Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V W Armstrong

Showing results (11-20 of 145) with videos related to

Pageof 15
Sort By:
Biochemistry|September 18, 1979
Mechanistic studies on deoxyribonucleic acid dependent ribonucleic acid polymerase from Escherichia coli using phosphorothioate analogues. 1. Initiation and pyrophosphate exchange reactionsD Yee, V W Armstrong, F Eckstein
Biochemistry|September 18, 1979
Mechanistic studies on deoxyribonucleic acid dependent ribonucleic acid polymerase from Escherichia coli using phosphorothioate analogues. 2. The elongation reactionV W Armstrong, D Yee, F Eckstein
FEBS Letters|November 1, 1976
Modification of an essential arginine in Escherichia coli DNA-dependent RNA polymeraseV W Armstrong, H Sternbach, F Eckstein
Drug Metabolism and Drug Interactions|January 1, 1997
Monitoring of cyclosporin and azathioprine in organ transplantationM Oellerich, E Schütz, V W Armstrong
Klinische Wochenschrift|October 1, 1980
Biochemical studies on patients undergoing continuous ambulatory peritoneal dialysisV W Armstrong, C Fuchs, F Scheler
Journal of Lipid Research|November 1, 1985
Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a)V W Armstrong, A K Walli, D Seidel
European Journal of Clinical Investigation|August 1, 1991
The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. HELP Study GroupD Seidel, V W Armstrong, P Schuff-Werner
Hepatology (Baltimore, Md.)|October 31, 1998
Monoethylglycinexylidide (MEGX) liver function test is not compromised by 3-hydroxy MEGX in humansE Schütz, M Shipkova, V W Armstrong, et al.
Lancet (London, England)|January 7, 1995
Apolipoprotein E in Creutzfeldt-Jakob diseaseI Zerr, M Helmhold, V W Armstrong, et al.
Clinical Biochemistry|October 26, 2001
Enzymatically degraded low density lipoproteins are more potent inducers of egr-1 mRNA than oxidized or native low density lipoproteinsE Stoyanova, A Tesch, V W Armstrong, et al.
Pageof 15

Showing results (11-20 of 145) with videos related to

Sort By:
Pageof 15
Biochemistry|September 18, 1979
Mechanistic studies on deoxyribonucleic acid dependent ribonucleic acid polymerase from Escherichia coli using phosphorothioate analogues. 1. Initiation and pyrophosphate exchange reactionsD Yee, V W Armstrong, F Eckstein
Biochemistry|September 18, 1979
Mechanistic studies on deoxyribonucleic acid dependent ribonucleic acid polymerase from Escherichia coli using phosphorothioate analogues. 2. The elongation reactionV W Armstrong, D Yee, F Eckstein
FEBS Letters|November 1, 1976
Modification of an essential arginine in Escherichia coli DNA-dependent RNA polymeraseV W Armstrong, H Sternbach, F Eckstein
Drug Metabolism and Drug Interactions|January 1, 1997
Monitoring of cyclosporin and azathioprine in organ transplantationM Oellerich, E Schütz, V W Armstrong
Klinische Wochenschrift|October 1, 1980
Biochemical studies on patients undergoing continuous ambulatory peritoneal dialysisV W Armstrong, C Fuchs, F Scheler
Journal of Lipid Research|November 1, 1985
Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a)V W Armstrong, A K Walli, D Seidel
European Journal of Clinical Investigation|August 1, 1991
The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. HELP Study GroupD Seidel, V W Armstrong, P Schuff-Werner
Hepatology (Baltimore, Md.)|October 31, 1998
Monoethylglycinexylidide (MEGX) liver function test is not compromised by 3-hydroxy MEGX in humansE Schütz, M Shipkova, V W Armstrong, et al.
Lancet (London, England)|January 7, 1995
Apolipoprotein E in Creutzfeldt-Jakob diseaseI Zerr, M Helmhold, V W Armstrong, et al.
Clinical Biochemistry|October 26, 2001
Enzymatically degraded low density lipoproteins are more potent inducers of egr-1 mRNA than oxidized or native low density lipoproteinsE Stoyanova, A Tesch, V W Armstrong, et al.
Pageof 15